☆ 4.6 Review

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma

CANCERS (2022)

Related references

Note: Only part of the references are listed.

Review Oncology

An Insight into Cholangiocarcinoma and Recent Advances in its Treatment

Rakesh Sahu et al.

Summary: This review focuses on various aspects of cholangiocarcinoma, including its associated causes and treatment criteria. Although cholangiocarcinoma is a rare malignancy, its incidence is increasing. Surgery remains the preferred treatment option for resectable patients, but recent reports suggest that targeted drugs may become an alternative choice.

JOURNAL OF GASTROINTESTINAL CANCER (2023)

Add to Collection

Article Gastroenterology & Hepatology

Controversial risk factors for cholangiocarcinoma

Firas Baidoun et al.

Summary: The study using a national inpatient database found that diabetes mellitus is associated with cholangiocarcinoma, while alcohol abuse, smoking, and obesity are inversely associated with cholangiocarcinoma. Compared to Whites, Hispanic and Asian/Pacific Islander races are more likely to have cholangiocarcinoma, whereas African American race is less likely to have cholangiocarcinoma.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

Laura Izquierdo-Sanchez et al.

Summary: This study investigates the clinical course of cholangiocarcinoma in a pan-European cohort and finds that the disease is frequently diagnosed at an advanced stage and a proportion of patients fail to receive cancer-specific therapies, resulting in a poor prognosis.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Cholangiocarcinoma protective factors in Greater Mekong Subregion: Critical issues for joint planning to sustainably solve regional public health problems

Nopparat Songserm et al.

Summary: This study aims to investigate the prevalence of protective factors for cholangiocarcinoma (CCA) incidence and identify significant factors associated with prevention. The survey results show a relatively high prevalence of protective factors in the region, which is of great importance for both the public and administrators. Women, individuals with higher education, and those with a higher level of awareness regarding the seriousness and benefits of CCA prevention are significantly associated with CCA prevention.

PLOS ONE (2022)

Add to Collection

Article Surgery

Factors associated with failure to rescue after major hepatectomy for perihilar cholangiocarcinoma: A 15-year single-center experience

Christian Benzing et al.

Summary: This study identifies independent risk factors for failure to rescue after major hepatectomy in perihilar cholangiocarcinoma. Elderly patients and those undergoing right-sided hepatectomy have a higher risk of failure to rescue. Preoperative carbohydrate antigen 19-9 levels and preoperative chemotherapy may also increase the odds of failure to rescue.

SURGERY (2022)

Add to Collection

Review Oncology

Utility of Cell-Free DNA Detection in Transplant Oncology

Tejaswini Reddy et al.

Summary: Transplant oncology is an emerging field that uses transplant medicine, surgery, and oncology to improve the survival and quality of life for cancer patients. cfDNA technology has revolutionized the management of cancer patients undergoing organ transplantation and allows for monitoring of tumor burden and transplant rejection.

CANCERS (2022)

Add to Collection

Review Oncology

Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis

Jessica J. Holster et al.

Summary: This systematic review examines the survival outcomes of hepatic arterial infusion pump (HAIP) chemotherapy with floxuridine for patients with unresectable intrahepatic cholangiocarcinoma (iCCA), and finds a 3-year overall survival rate of 39.5%.

ANNALS OF SURGICAL ONCOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Predictive factors for subsequent intrahepatic cholangiocarcinoma associated with hepatolithiasis: Japanese National Cohort Study for 18 years

Yutaka Suzuki et al.

Summary: This study aimed to investigate the predictive factors for developing intrahepatic cholangiocarcinoma in hepatolithiasis. The results showed that age, residual stones at the end of treatment, and biliary stricture during follow-up were identified as independent and significant predictive factors. Patients with all three factors had a higher risk of developing intrahepatic cholangiocarcinoma compared to those with fewer factors. The duration between the diagnoses of biliary stricture and intrahepatic cholangiocarcinoma was over 5 years in most cases.

JOURNAL OF GASTROENTEROLOGY (2022)

Add to Collection

Article Oncology

Effectiveness of Village Health Volunteer Parallel Program for Proactive Action to Reduce Risk Factors for Cholangiocarcinoma in Two High-Risk Countries in the Greater Mekong Subregion

Nopparat Songserm et al.

Summary: By training village health volunteers to educate locals on the prevention of cholangiocarcinoma, the program effectively reduced risk factors in the risk areas, showing promise for application in other regions.

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2022)

Add to Collection

Review Oncology

Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View

Maen Abdelrahim et al.

Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths globally. Liver transplantation is not suitable for advanced stage HCC patients with large tumors. Immune checkpoint inhibitors have shown promising results in HCC treatment, but there are concerns about organ rejection in liver transplant patients.

CANCERS (2022)

Add to Collection

Article Oncology

Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series

Maen Abdelrahim et al.

Summary: This study validates the potential efficacy of neo-adjuvant chemotherapy with Gemcitabine and Cisplatin in cholangiocarcinoma patients before liver transplantation, resulting in excellent outcomes.

CURRENT ONCOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Antibody-drug conjugates in HER2-positive breast cancer

Lixi Li et al.

Summary: Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs, and have shown potential as a promising treatment option for breast cancer and other tumors.

CHINESE MEDICAL JOURNAL (2022)

Add to Collection

Article

Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review

Silvia Bisello et al.

Molecular and Clinical Oncology (2021)

Add to Collection

Article Oncology

Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity-matched National Cancer Database analysis

Sivesh K. Kamarajah et al.

Summary: Adjuvant radiotherapy after resection of distal cholangiocarcinoma was associated with a survival benefit in patients, even in patients with margin-negative or node-negative resections. Adjuvant radiotherapy should be considered routinely irrespective of margin and nodal status after resection of distal cholangiocarcinoma.

CANCER (2021)

Add to Collection

Meeting Abstract Oncology

Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.

Funda Meric-Bernstam et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Surgical Therapy for Perihilar Cholangiocarcinoma: State of the Art

Lynn E. Nooijen et al.

Summary: Collaboration between leading centers is crucial to optimize long-term outcomes for patients with pCCA. Large prospective randomized controlled trials are needed due to the low incidence of pCCA and limited number of resectable patients. Current evidence is based on small retrospective cohort studies, and trials are necessary to confirm the positive effects of preoperative chemotherapy and extended lymph node resection for improving long-term survival.

VISCERAL MEDICINE (2021)

Add to Collection

Review Oncology

Targeting FGFR inhibition in cholangiocarcinoma

Lipika Goyal et al.

Summary: CCAs, particularly iCCAs, often have therapeutic implications from somatic alterations such as FGFR2 fusions or rearrangements. Clinical trials for FGFR kinase inhibitors have shown consistent activity in previously treated iCCA patients with FGFR alterations, although differences in structure, mechanisms, and specificities remain to be fully characterized. Managing adverse events such as hyperphosphatemia and monitoring for acquired resistance are essential as FGFR inhibitors and other targeted agents are used in the clinic for FGFR-driven CCA.

CANCER TREATMENT REVIEWS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAFV600E-Mutant CRC: A Case Report and Review

Su Min Cho et al.

Summary: Approximately 10% of colorectal cancer cases exhibit mutations in the BRAF proto-oncogene, most commonly the V600E mutation. These BRAF-mutant CRC cases have shown limited response to traditional therapies and poor survival rates. A 75-year-old man with BRAF(V600E)-mutant CRC achieved complete response and remission after 40 cycles of the vemurafenib, irinotecan, and cetuximab (VIC) regimen, which was based on the SWOG 1406 trial and highlighted the effectiveness of BRAF(V600E) and EGFR inhibitors in combination therapy.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Review Oncology

Transplant Oncology: An Evolving Field in Cancer Care

Maen Abdelrahim et al.

Summary: Transplant oncology is a promising concept that combines oncology, transplant medicine, and surgery to improve patient survival and quality of life, especially for hepatobiliary malignancies. Liver transplantation has shown significant improvement in treating hepatobiliary malignancies and CRC patients with liver metastases, but its indications only improve patient survival in the setting of limited systemic therapy options.

CANCERS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Milind Javle et al.

Lancet Gastroenterology & Hepatology (2021)

Add to Collection

Review Immunology

Immunotherapy for cholangiocarcinoma: a 2021 update

Nikolaos Charalampakis et al.

Summary: Cholangiocarcinoma is a rare malignancy with poor prognosis, and while immunotherapy has significantly improved cancer patient management in the past decade, challenges remain in treating CCA. Research on novel immunotherapeutic methods and identifying valuable biomarkers for treatment response are ongoing in order to advance treatment options for patients with CCA.

IMMUNOTHERAPY (2021)

Add to Collection

Meeting Abstract Oncology

Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.

Keun Wook Lee et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Biotechnology & Applied Microbiology

Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer

Seda Kahraman et al.

Summary: Gastric cancer is the fifth most common cancer worldwide, with advanced cases being particularly difficult to cure. Treatment efforts focus on improving quality of life, tumor response rate, and survival while balancing therapy toxicities. The only available biomarkers for guiding treatment are HER2 overexpression, MSI/PD-L1 status, and FGFR alterations.

ONCOTARGETS AND THERAPY (2021)

Add to Collection

Article Medicine, General & Internal

Cholangiocarcinoma

Paul J. Brindley et al.

Summary: Cholangiocarcinoma is a highly lethal adenocarcinoma of the hepatobiliary system that can be associated with liver fluke infection but often has no identifiable cause. This Primer reviews the epidemiology, pathophysiological mechanisms, diagnosis and management of cholangiocarcinoma, and highlights the patient experience and future directions.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Article Oncology

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation The Phase 3 Randomized Clinical ClarIDHy Trial

Andrew X. Zhu et al.

Summary: The study found that ivosidenib was well tolerated and led to a favorable overall survival benefit compared to placebo, despite a high crossover rate.

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology

FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements.

Tanios S. Bekaii-Saab et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma

Bixin Ren et al.

RADIATION ONCOLOGY (2020)

Add to Collection

Review Oncology

Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer

Chennianci Zhu et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2020)

Add to Collection

Article Oncology

FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.

Lipika Goyal et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

Phillip C. C. Liu et al.

PLOS ONE (2020)

Add to Collection

Article Oncology

Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ghassan K. Abou-Alfa et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou-Alfa et al.

LANCET ONCOLOGY (2020)

Add to Collection

Review Oncology

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

Charles Pottier et al.

CANCERS (2020)

Add to Collection

Article Oncology

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial

Shalini Makawita et al.

FUTURE ONCOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Jesus M. Banales et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

Add to Collection

Review Oncology

Latest evidence on immunotherapy for cholangiocarcinoma

Xurui Guo et al.

ONCOLOGY LETTERS (2020)

Add to Collection

Review Biology

Systemic treatment of advanced or recurrent biliary tract cancer

Wei Zhang et al.

BIOSCIENCE TRENDS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

Paola Bertuccio et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Review Medicine, General & Internal

Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials

Maria Maddalena Simile et al.

MEDICINA-LITHUANIA (2019)

Add to Collection

Review Cell Biology

Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors

Shuyan Dai et al.

CELLS (2019)

Add to Collection

Article Oncology

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Vincenzo Mazzaferro et al.

BRITISH JOURNAL OF CANCER (2019)

Add to Collection

Review Oncology

Biological Role and Therapeutic Potential of IDH Mutations in Cancer

Matthew S. Waitkus et al.

CANCER CELL (2018)

Add to Collection

Article Oncology

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

Milind Javle et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype

Apurva Jain et al.

JCO PRECISION ONCOLOGY (2018)

Add to Collection

Article Oncology

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

Teresa Helsten et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection

Review Oncology

IDH mutations in cancer and progress toward development of targeted therapeutics

L. Dang et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Gastroenterology & Hepatology

Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database

Kaelan J. Yao et al.

BMC GASTROENTEROLOGY (2016)

Add to Collection

Review Oncology

Antibody-drug conjugates-an emerging class of cancer treatment

Nikolaos Diamantis et al.

BRITISH JOURNAL OF CANCER (2016)

Add to Collection

Article Medicine, Research & Experimental

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study

Grazia Palomba et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2016)

Add to Collection

Article Gastroenterology & Hepatology

Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

Jesus M. Banales et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)

Add to Collection

Article Oncology

Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Enterologues Oncologues

Bertrand Brieau et al.

CANCER (2015)

Add to Collection

Review Oncology

The Global Burden of Cancer 2013 Global Burden of Disease Cancer Collaboration

Christina Fitzmaurice et al.

JAMA ONCOLOGY (2015)

Add to Collection

Review Oncology

Multiple molecular pathways in melanomagenesis: characterization of therapeutic targets

Giuseppe Palmieri et al.

FRONTIERS IN ONCOLOGY (2015)

Add to Collection

Article Hematology

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition

Andrew Kernytsky et al.

BLOOD (2015)

Add to Collection

Review Oncology

Second-line chemotherapy in advanced biliary cancer: a systematic review

A. Lamarca et al.

ANNALS OF ONCOLOGY (2014)

Add to Collection

Meeting Abstract Oncology

Second-line systemic treatment for advanced cholangiocarcinoma

Jane Elizabeth Rogers et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Gastroenterology & Hepatology

Roles of liver fluke infection as risk factor for cholangiocarcinoma

Paiboon Sithithaworn et al.

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2014)

Add to Collection

Article Gastroenterology & Hepatology

Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes

Daniela Sia et al.

GASTROENTEROLOGY (2013)

Add to Collection

Article Multidisciplinary Sciences

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang et al.

SCIENCE (2013)

Add to Collection

Article Multidisciplinary Sciences

IDH mutation impairs histone demethylation and results in a block to cell differentiation

Chao Lu et al.

NATURE (2012)

Add to Collection

Article Multidisciplinary Sciences

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

Sevin Turcan et al.

NATURE (2012)

Add to Collection

Article Tropical Medicine

The global epidemiology of clonorchiasis and its relation with cholangiocarcinoma

Men-Bao Qian et al.

Infectious Diseases of Poverty (2012)

Add to Collection

Review Gastroenterology & Hepatology

Clinical diagnosis and staging of cholangiocarcinoma

Boris Blechacz et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)

Add to Collection

Article Oncology

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

Maria E. Figueroa et al.

CANCER CELL (2010)

Add to Collection

Article Medicine, General & Internal

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.

Juan Valle et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Review Oncology

Fibroblast growth factor signalling: from development to cancer

Nicholas Turner et al.

NATURE REVIEWS CANCER (2010)

Add to Collection

Article Multidisciplinary Sciences

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Lenny Dang et al.

NATURE (2009)

Add to Collection

Article Medicine, General & Internal

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

Elaine R. Mardis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Add to Collection

Article Gastroenterology & Hepatology

Cholangiocarcinoma complicating primary sclerosing cholangitis: A 24-year experience

G. Morris-Stiff et al.

DIGESTIVE SURGERY (2008)

Add to Collection

Review Biochemistry & Molecular Biology

Cellular signaling by fibroblast growth factor receptors

VP Eswarakumar et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2005)

Add to Collection

Review Biotechnology & Applied Microbiology

Monoclonal antibody therapy of cancer

GP Adams et al.

NATURE BIOTECHNOLOGY (2005)

Add to Collection

Article Oncology

The role of chemotherapy in cholangiocarcinoma

S Thongprasert

ANNALS OF ONCOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.